Thierry Virolle

Dr. Thierry Virolle

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Glioblastomas (GBM) are heterogeneous tumors with high metabolic plasticity. Their poor prognosis is linked to the presence of glioblastoma stem cells (GSC), which support resistance to therapy, notably to temozolomide (TMZ). Mesenchymal stem cells (MSC) recruitment to GBM contributes to GSC chemoresistance, by mechanisms still poorly understood. Here, we provide evidence that MSCs transfer mitochondria to GSCs through tunneling nanotubes, which enhances GSCs resistance to TMZ. More precisely, our metabolomics analyses reveal that MSC mitochondria induce GSCs metabolic reprograming, with a nutrient shift from glucose to glutamine, a rewiring of the tricarboxylic acid cycle from glutaminolysis to reductive carboxylation and increase in orotate turnover as well as in pyrimidine and purine synthesis. Metabolomics analysis of GBM patient tissues at relapse after TMZ treatment documents increased concentrations of AMP, CMP, GMP, and UMP nucleotides and thus corroborate our in vitro analyses. Finally, we provide a mechanism whereby mitochondrial transfer from MSCs to GSCs contributes to GBM resistance to TMZ therapy, by demonstrating that inhibition of orotate production by Brequinar (BRQ) restores TMZ sensitivity in GSCs with acquired mitochondria. Altogether, these results identify a mechanism for GBM resistance to TMZ and reveal a metabolic dependency of chemoresistant GBM following the acquisition of exogenous mitochondria, which opens therapeutic perspectives based on synthetic lethality between TMZ and BRQ.Significance: Mitochondria acquired from MSCs enhance the chemoresistance of GBMs. The discovery that they also generate metabolic vulnerability in GSCs paves the way for novel therapeutic approaches.

30 October 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MSMirca S. Saurty-Seerunghen
Mirca S. Saurty-Seerunghen
Thomas DaubonThomas Daubon
Thomas Daubon
LBLéa Bellenger
Léa Bellenger
VDVirgile Delaunay
Virgile Delaunay
GCGloria Castro
Gloria Castro
MJMarie-pierre Junier
Marie-pierre Junier
Cell motility is critical for tumor malignancy. Metabolism being an obligatory step in shaping cell behavior, we looked for metabolic weaknesses shared by motile cells across the diverse genetic contexts of patients’ glioblastoma. Computational analyses of single-cell transcriptomes from thirty patients’ tumors isolated cells with high motile potential and highlighted their metabolic specificities. These cells were characterized by enhanced mitochondrial load and oxidative stress coupled with mobilization of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase (MPST). Functional assays with patients’ tumor-derived cells and -tissue organoids, and genetic and pharmacological manipulations confirmed that the cells depend on enhanced ROS production and MPST activity for their motility. MPST action involved protection of protein cysteine residues from damaging hyperoxidation. Its knockdown translated in reduced tumor burden, and a robust increase in mice survival. Starting from cell-by-cell analyses of the patients’ tumors, our work unravels metabolic dependencies of cell malignancy maintained across heterogeneous genomic landscapes.

18 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LTLaurent Turchi
Laurent Turchi
NSNathalie Sakakini
Nathalie Sakakini
GSGaelle SAVIANE
Gaelle SAVIANE
BPBeatrice Polo
Beatrice Polo
MSMirca Saras Saurty-Seerunghen
Mirca Saras Saurty-Seerunghen
TVThierry Virolle
Thierry Virolle
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.

Verified
Journal Article
Open access
PDF file
DCDavid CHARDIN
David CHARDIN
LJLun JING
Lun JING
MCMélanie Chazal-Ngo-Mai
Mélanie Chazal-Ngo-Mai
JGJean-Marie Guigonis
Jean-Marie Guigonis
VRValerie Rigau
Valerie Rigau
FBFanny BUREL-VANDENBOS
Fanny BUREL-VANDENBOS
The aim of this study was to identify metabolomic signatures associated with the gliomagenesis pathway (IDH-mutant or IDH-wt) and tumor grade of diffuse gliomas (DGs) according to the 2021 WHO classification on frozen samples and to evaluate the diagnostic performances of these signatures in tumor samples that are formalin-fixed and paraffin-embedded (FFPE). An untargeted metabolomic study was performed using liquid chromatography/mass spectrometry on a cohort of 213 DG samples. Logistic regression with LASSO penalization was used on the frozen samples to build classification models in order to identify IDH-mutant vs. IDH-wildtype DG and high-grade vs low-grade DG samples. 2-Hydroxyglutarate (2HG) was a metabolite of interest to predict IDH mutational status and aminoadipic acid (AAA) and guanidinoacetic acid (GAA) were significantly associated with grade. The diagnostic performances of the models were 82.6% AUC, 70.6% sensitivity and 80.4% specificity for 2HG to predict IDH status and 84.7% AUC, 78.1% sensitivity and 73.4% specificity for AAA and GAA to predict grade from FFPE samples. Thus, this study showed that AAA and GAA are two novel metabolites of interest in DG and that metabolomic data can be useful in the classification of DG, both in frozen and FFPE samples.

25 May 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Effects of MSC mitochondria on GSCs metabolic response to TMZ (A, B) GSC mitochondrial mass and ROS production. FACS analysis of MitoTracker and MitoSox-labeled GSCs after the acquisition of MSC mitochondria and TMZ treatment (24 hr). (A) Mitochondrial mass. (B) ROS production. (A, B) Representative experiments and relative MFI values (mean ± SEM; n=3). One-way ANOVA, *p < 0.05. (C) Expression of Cytochrome c oxidase IV (COX IV). Representative Western blot with the corresponding membrane (MW markers in kDa) as shown in Fig. 3H.

25 May 2023
Verified
Other
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Metabolites produced by GSCs following MSC mitochondria acquisition and TMZ treatment